Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625401 | 0.93 | GNRHR (0.73) | GNRHRCYP3A4 | |
| SCHEMBL5757354 | 0.90 | GNRHR (1.00) | GNRHR | |
| SCHEMBL6614650 | 0.90 | GNRHR (1.00) | GNRHR | |
| SCHEMBL6614653 | 0.90 | GNRHR (1.00) | GNRHR | |
| SCHEMBL5757889 | 0.89 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL5758684 | 0.88 | GNRHR (0.69) | GNRHR | |
| SCHEMBL5760325 | 0.88 | GNRHR (0.84) | GNRHRCYP3A4 | |
| SCHEMBL5759244 | 0.85 | GNRHR (0.85) | GNRHRCYP3A4 | |
| SCHEMBL5756746 | 0.84 | GNRHR (0.84) | GNRHRCYP3A4 | |
| SCHEMBL5755661 | 0.84 | GNRHR (0.83) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412338-B1 | 1,3,5-TRIAZINE-2,4,6-TRIONES, PREPARATION AND USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040162290-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-19 | — | — | US | disclosed |
| EP-1412338-A1 | 1,3,5-TRIAZINE-2,4,6-TRIONES, PREPARATION AND USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | Neurocrine Biosciences, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6677340-B2 | ADMINISTERING HEXAHYDRO-1,3-5-TRIAZINE-2,4,6-TRIONE DERIVATIVE AS ANTICARCINOGENIC AGENT; BENIGN PROSTATIC HYPERPLASIA, SLEEP DISORDER TREATMENT | NEUROCRINE BIOSCIENCES, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030130282-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003011839-A1 | 1,3,5-TRIAZINE-2,4,6-TRIONES, PREPARATION AND USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130282-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1088/4885 |
| US-20040162290-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.